Role of KIRs and KIR ligands in hematopoietic transplantation

Current Opinion in Immunology

Volumn 20, Issue 5, 2008, Pages 581-587

  Velardi, Andrea ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A1 ANTIGEN; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CORD BLOOD STEM CELL TRANSPLANTATION; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA TYPING; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; NATURAL KILLER CELL; RECIPIENT; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; RECEPTORS, KIR; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 50549099901     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.07.004     Document Type: Review

References (57)

1. ••].
2. ••].
3. ••].
4. ••], this is an excellent update on recent advances in NK cell biology and critically reviews genetic and functional evidence on how inhibitory recognition of class I molecules regulates NK cell tolerance to self and alloreactivity.
5. Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 178 (2007) 33-37
6. Foley B.A., De Santis D., Van Beelen E., Lathbury L.J., Christiansen F.T., and Witt C.S. The reactivity of Bw4-positive HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplants. Blood 112 (2008) 435-443
7. Stern M., Ruggeri L., Capanni M., Mancusi A., and Velardi A. Human leukocyte antigens A23, A24 and A32 but not A25 are ligands for KIR3DL1. Blood 112 (2008) 708-710
8. Fernandez N.C., Treiner E., Vance R.E., Jamieson A.M., Lemieux S., and Raulet D.H. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105 (2005) 4416-4423
9. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., French A.R., Sunwoo J.B., Lemieux S., Hansen T.H., and Yokoyama W.M. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005) 709-713
10. Anfossi N., André P., Guia S., Falk C.S., Roetynck S., Stewart C.A., Breso V., Frassati C., Reviron D., Middleton D., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2 (2006) 331-342. The first demonstration of the existence of NK cells with inhibitory HLA receptors which do not recognize self HLA. They are retained in the repertoire in a 'hypofunctional' state.
11. Moretta L., and Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 16 (2004) 626-633
12. Ciccone E., Pende D., Viale O., Di Donato C., Tripodi G., Orengo A.M., Guardiola J., Moretta A., and Moretta L. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 175 (1992) 709-718
13. Colonna M., Brooks E.G., Falco M., Ferrara G.B., and Strominger J.L. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260 (1993) 1121-1124
14. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., Phillips J.H., Lanier L.L., and Parham P. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7 (1997) 739-751
15. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., and Caligiuri M. Natural Killer cell receptors: new biology and insights into the graft versus leukemia effect. Blood 100 (2002) 1935-1947
16. Velardi A., Ruggeri L., Moretta A., and Moretta L. NK-cells: a lesson from mismatched haematopoietic transplantation. Trends Immunol 23 (2002) 438-444
17. Parham P., and McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 3 (2003) 108-122
18. Ruggeri L., Aversa F., Martelli M.F., and Velardi A. Haploidentical transplantation and natural killer cell recognition of missing self. Immunol Rev 214 (2006) 202-218
19. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., Tyan D., Lanier L.L., and Parham P. Human diversity in killer-cell inhibitory receptor genes. Immunity 7 (1997) 753-763
20. Ruggeri L., Capanni M., Casucci M., Volpi I., Tosti A., Perruccio K., Urbani E., Negrin R.S., Martelli M.F., and Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
21. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
22. Kärre K. A perfect mismatch. Science 295 (2002) 2029-2031
23. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., Stern M., Pende D., Perruccio K., Burchielli E., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 (2007) 433-440. This study provided definitive evidence for the favorable impact of donor NK cell allorecognition of KIR ligand mismatches in a large series of haploidentical transplants and challenged its predictive value by comparing it with the 'missing ligand' model (see below).
24. Hsu K.C., Chida S., Geraghty D.E., and Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190 (2002) 40-52
25. Pando M.J., Gardiner C.M., Gleimer M., McQueen K.L., and Parham P. The protein made from a common allele of KIR3DL1 (3DL*004) is poorly expressed at cell surfaces due to substitution at position 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 171 (2003) 6640-6647
26. Thomas R., Yamada E., Alter G., Martin M.P., Bashirova A.A., Norman P.J., Altfeld M., Parham P., Anderson S.K., McVicar D.W., and Carrington M. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?. J Immunol 180 (2008) 6743-6750
27. Igarashi T., Wynberg J., Srinivasan R., Becknell B., McCoy Jr. J.P., Takahashi Y., Suffredini D.A., Linehan W.M., Caligiuri M.A., and Childs R.W. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104 (2004) 170-177
28. Stern M, Ruggeri L, Mancusi A, Bernardo ME, De Angelis C, Bucher C, Locatelli F, Aversa F, Velardi A: Survival after T-cell depleted haploidentical stem cell transplantation is improved with mothers as donors. Blood 2008, in press (Epub ahead of print May 20, 2008). This study showed NK cell alloreactivity provided much better protection from leukemia relapse when exerted by maternal donors.
29. Hansasuta P., Dong T., Thananchai H., Weekes M., Willberg C., Aldemir H., Rowland-Jones S., and Braud V.M. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 34 (2004) 1673-1679
30. Cooley S., McCullar V., Wangen R., Bergemann T.L., Spellman S., Weisdorf D.J., and Miller J.S. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106 (2005) 4370-4376
31. Davies S.M., Ruggeri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., Velardi A., and Blazar B.R. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 100 (2002) 3825-3827
32. Lowe E.J., Turner V., Handgretinger R., Horwitz E.M., Benaim E., Hale G.A., Woodard P., and Leung W. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 123 (2003) 323-326
33. Bornhauser M., Schwerdtfeger R., Martin H., Frank K.H., Theuser C., and Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103 (2004) 2860-2861
34. Farag S.S., Bacigalupo A., Eapen M., Hurley C., Dupont B., Caligiuri M.A., Boudreau C., Nelson G., Oudshoorn M., van Rood J., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12 (2006) 876-884
35. Hsu K.C., Gooley T., Malkki M., Pinto-Agnello C., Dupont B., Bignon J.D., Bornhäuser M., Christiansen F., Gratwohl A., Morishima Y., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transpl 12 (2006) 828-836. See annotation to Ref. [45].
36. Kröger N., Binder T., Zabelina T., Wolschke C., Schieder H., Renges H., Ayuk F., Dahlke J., Eiermann T., and Zander A. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 82 (2006) 1024-1030
37. Yabe T., Matsuo K., Hirayasu K., Kashiwase K., Kawamura-Ishii S., Tanaka H., Ogawa A., Takanashi M., Satake M., Nakajima K., et al., Japan Marrow Donor Program. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 14 (2008) 75-87
38. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., Maccario R., Bonetti F., Wojnar J., Martinetti M., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
39. Beelen D.W., Ottinger H.D., Ferencik S., Elmaagacli A.H., Peceny R., Trenschel R., and Grosse-Wilde H. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105 (2005) 2594-2600
40. Elmaagacli A.H., Ottinger H., Koldehoff M., Peceny R., Steckel N.K., Trenschel R., Biersack H., Grosse-Wilde H., and Beelen D.W. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 79 (2005) 1741-1747
41. Kröger N., Shaw B., Iacobelli S., Zabelina T., Peggs K., Shimoni A., Nagler A., Binder T., Eiermann T., Madrigal A., et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129 (2005) 631-643
42. Dawson M.A., and Spencer A. Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. J Clin Oncol 23 (2005) 4473-4474
43. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., Niethammer D., and Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172 (2004) 644-650
44. Leung W., Iyengar R., Triplett B., Turner V., Behm F.G., Holladay M.S., Houston J., and Handgretinger R. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174 (2005) 6540-6545
45. Dupont B., and Hsu K.C. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in hematopoietic stem cell transplantation. Curr Opin Immunol 16 (2004) 623-626
46. Hsu K.C., Keever-Taylor C.A., Wilton A., Pinto C., Heller G., Arkun K., O'Reilly R.J., Horowitz M.M., and Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
47. Hsu K.C., Pinto-Agnello C., Gooley T., Malkki M., Dupont B., and Petersdorf E.W. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 69 Suppl 1 (2007) 42-45. See annotation to Ref. [45].
48. •], this reference shows the role of the missing ligand effect in large unrelated donor transplant cohorts. The missing ligand model postulates NK alloreactions also occur when KIR ligand-matched donors possess an 'extra' KIR for which neither donor nor recipient has HLA ligand(s).
49. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5 (2005) 201-214
50. Verheyden S., Schots R., Duquet W., and Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukaemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19 (2005) 1446-1451
51. De Santis D., Bishara A., Witt C.S., Nagler A., Brautbar C., Slavin S., and Christiansen F.T. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 65 (2005) 519-528
52. Cook M., Briggs D., Craddock C., Mahendra P., Milligan D., Fegan C., Darbyshire P., Lawson S., Boxall E., and Moss P. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107 (2006) 1230-1232
53. Chen C., Busson M., Rocha V., Appert M.L., Lepage V., Dulphy N., Haas P., Socié G., Toubert A., Charron D., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 38 (2006) 437-444
54. Cook M.A., Milligan D.W., Fegan C.D., Darbyshire P.J., Mahendra P., Craddock C.F., Moss P.A., and Briggs D.C. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling haematopoietic stem cell transplantation for myeloid leukemia. Blood 103 (2004) 1521-1526
55. Bishara A., De Santis D., Witt C.C., Brautbar C., Christiansen F.T., Or R., Nagler A., and Slavin S. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 (2004) 204-211
56. Sun J.Y., Gaidulis L., Dagis A., Palmer J., Rodriguez R., Miller M.M., Forman S.J., and Senitzer D. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 36 (2005) 525-530
57. McQueen K.L., Dorighi K.M., Guethlein L.A., Wong R., Sanjanwala B., and Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68 (2007) 309-323